Back to Search
Start Over
Tazarotene scales ahead in the psoriasis cost-effectiveness stakes
- Source :
- Inpharma Weekly. :7
- Publication Year :
- 1998
- Publisher :
- Springer Science and Business Media LLC, 1998.
-
Abstract
- Although psoriasis is perceived to have a limited effect on the cost of US healthcare, the reality is very different. Psoriasis is a persistent and progressive skin disorder that affects about 6 million people in the US, with 250 000 new cases diagnosed every year. Depending on disease severity, annual outpatient care can cost $US1400-$US6600 per patient, representing a total national cost of $US3.2 billion/year in the US. According to investigators from Health Economics Research, New Jersey, US, the high cost of care for selected patients with mild-to-moderate psoriasis can be reduced by using the new topical retinoid tazarotene.1At the recent 56th Annual Meeting of the American Dermatology Association [Orlando, US; March 1998], the investigators presented the results of a pharmacoeconomic model of monotherapy with either tazarotene, fluocinonide or calcipotriol for patients with mild-to-moderate stable plaque psoriasis. *
Details
- ISSN :
- 11738324
- Database :
- OpenAIRE
- Journal :
- Inpharma Weekly
- Accession number :
- edsair.doi.dedup.....70fe40c2d6cc759213c9fb18058c95fc
- Full Text :
- https://doi.org/10.2165/00128413-199811350-00011